Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

18th International Meeting of the European Society of Gynaecological Oncology (ESGO) /
Results of the ICON7, phase III clinical trial

19th - 22nd Oct 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.11.13
Views: 4591
Rating:

Prof Eric Pujade-Lauraine - Université de Paris Descartes, France

Prof Eric Pujade Lauraine talks to ecancer at the 2013 ESGO meeting in Liverpool about the results of the ICON7 study.

ICON7 is a phase III randomised trial that looks at standard chemotherapy with or without bevacizumab in advanced ovarian cancer and measures the quality of life of the outcomes.

ecancer's filming at ESGO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

 

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation